Bioventus Launches SUPARTZ FX™Now with Expanded Safety Label for Repeat Injection Cycles in Knee Osteoarthritis

DURHAM, NC – October 12, 2015 – Bioventus, a global leader in orthobiologics, today announced the launch of SUPARTZ FX™, a broadening of its current hyaluronic acid (HA) offering. SUPARTZ FX has an expanded label allowing for repeat injection cycles to help knee osteoarthritis (OA) patients manage pain and remain active. More effective for pain and function than nonsteroidal anti-inflammatory drugs and corticosteroids, hyaluronic acids such as SUPARTZ FX is a safe and effective treatment for knee OA.1, 2*, 3

SUPARTZ FX helps restore the body’s natural HA production which may help preserve lubricity of bearing joint surfaces such as the knee and HA products, like SUPARTZ FX, may also delay the need for total knee replacement.2, 4

“SUPARTZ FX builds upon the success of SUPARTZ and ARTZ to alleviate OA knee pain and since the introduction of SUPARTZ, more than 300 million injections of this HA have been prescribed globally,” said Tony Bihl, CEO, Bioventus. “The clinically proven expanded label allows Bioventus to continue to provide physicians and patients with an OA treatment that is safe for repeat courses of treatment.”5.

On sale now, SUPARTX FX is only available in the U.S. Contact your doctor or visit to learn more.

About Bioventus

Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

Media Contact: Thomas Hill   [email protected]

*Based on effect sizes for pain and function at 3 months; statistically significant for pain in comparison to acetaminophen, celecoxib, and naproxen and for function in comparison to corticosteroids SUPARTZ FX (also called a viscosupplement) is a non-surgical, non-pharmacologic therapy for knee osteoarthritis.

Indications: SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to avian (bird) products (feathers and eggs. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found at or by contacting customer service at 800-836-4080.

Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

SUPARTZ and ARTZ are registered trademarks and SUPARTZ FX is a trademark of Seikagaku.

1. Tehranzadeh J, Booya F, Root J. Cartilage metabolism in osteoarthritis and the influence of viscosupplementation and steroid: a review. Acta Radiol. 2005;46(3):288-296.

2. Altman R, Lim S, Steen RG, Dasa V. Intra-articular hyaluronic acid delays total knee replacement (TKR) in patients with knee OA: evidence from a large U.S. health claims database. OARSI poster 674. Osteoarthritis Cartilage 2015;23(2):A403.

3. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. MD Ann Intern Med. 2015;162(1):46-54. doi:10.7326/M14-1231.

4. Kusayama Y, Akamatsu Y, Kumagai K, Kobayashi H, Aratake M, Saito T. Changes in synovial fluid biomarkers and clinical efficacy of intra-articular injections of hyaluronic acid for patients with knee osteoarthritis. J Exp Orthop. 2014;1:16.

5. RPT-000309 Data on File DOF 12000.29. Based on Seikagaku Corporation Annual Report 2013.